Alzheimer's Disease Trial, Recruiting NCT06481878 Sponsor: University Hospital, Grenoble Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT06481878
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People with Alzheimer's disease and significant memory or thinking difficulties:

  • People diagnosed with Alzheimer's disease using recognised diagnostic guidelines (IWG 2021), at a stage of major (significant) cognitive impairment
  • People aged 40 or older
  • People who have a caregiver or support person available
  • People who have not formally objected to taking part

People with Alzheimer's disease and mild memory or thinking difficulties:

  • People diagnosed with Alzheimer's disease using recognised diagnostic guidelines (IWG 2021), at a stage of minor (mild) cognitive impairment
  • People aged 40 or older
  • People who have not formally objected to taking part

People with mild or significant cognitive impairment who do NOT have Alzheimer's disease (based on spinal fluid tests showing no Alzheimer's markers):

  • People with mild or significant cognitive impairment whose spinal fluid test results show no Alzheimer's disease markers (classified as A- T-)
  • People aged 40 or older
  • People who have not formally objected to taking part

People with mild cognitive impairment whose spinal fluid test results are mixed or uncertain:

  • People with mild cognitive impairment whose spinal fluid results show only some Alzheimer's markers (either A+ T- or A- T+, meaning results do not fully confirm or fully rule out Alzheimer's) (confirm with trial site)
  • People aged 40 or older
  • People who have not formally objected to taking part

Healthy volunteers:

  • People with no concerns or complaints about their memory or thinking
  • People who score 26 or above on a standard memory and thinking test (MMSE)
  • People who show no signs of cognitive impairment on a standard assessment (CDR score of 0)
  • People aged 40 or older
  • People who have not formally objected to taking part

Who may not be able to join:

For all participant groups:

  • People who are unable to understand the study instructions or to formally indicate whether they object to taking part
  • People who are not affiliated with or covered by a social security plan or equivalent scheme (this appears to be a French healthcare system requirement — confirm with trial site)
  • People who are legally protected adults or who are under administrative or judicial supervision, as covered under specific French public health law (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mathilde SAUVEE, University Hospital, Grenoble

Phone: 33 (0)4 76 76 57 90

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
11 October 2024
Est. completion
6 October 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

to determine the amount of fibrillar and oligomeric amyloid peptide and phosphorylated tau protein measured in the stools of subjects issued as soon as possible after recruitment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov